Treatment With Anti-VEGF Antibodies

Abstract

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

1 . A method of treating metastatic ovarian cancer in a human patient, comprising administering to the patient effective amounts of an anti-VEGF antibody and an anti-neoplastic composition, wherein said anti-neoplastic composition comprises at least one chemotherapeutic agent and wherein said anti-VEGF antibody is bevacizumab. 
     
     
         2 . The method of  claim 1 , wherein the anti-VEGF antibody is administered concomitantly with the at least one chemotherapeutic agent. 
     
     
         3 . The method of  claim 1 , wherein the patient is previously untreated. 
     
     
         4 . The method of  claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouricil, leucovorin, irinotecan, oxaliplatin, capecetabine, paclitaxel and doxetaxel. 
     
     
         5 . The method of  claim 4 , wherein the chemotherapeutic agent additionally comprises a platinum coordination complex. 
     
     
         6 . The method of  claim 5 , wherein the chemotherapeutic agent is paclitaxel. 
     
     
         7 . The method of  claim 6 , wherein the platinum coordination complex is carboplatin. 
     
     
         8 . The method of  claim 1 , wherein the anti-VEGF antibody is administered intravenously. 
     
     
         9 . The method of  claim 8 , wherein the anti-VEGF antibody is administered to the patient at about 5 mg/kg to about 15 mg/kg every 2 to 3 weeks. 
     
     
         10 . The method of  claim 9 , wherein the anti-VEGF antibody is administered by intravenous infusion over 30-90 minutes. 
     
     
         11 . The method of  claim 10 , wherein the anti-VEGF antibody is administered to the patient at 15 mg/kg every 3 weeks.